AI Timing Demand, Cybersecurity Strength, and an Oil Beat That Needs Context

One company is becoming a bigger part of the AI infrastructure stack as precision timing demand accelerates. Another delivered a clean cybersecurity beat with strong product growth and record margins, while an oil major showed strong profits but a less exciting capital-return setup. The numbers are strong, but the calls are not the same.

One drug company is making nearly $1 billion a year treating a recurring heart condition with a weekly injection - and 82% of eligible patients still aren't on therapy.

Now a small biotech is developing an oral alternative. Its mid-stage trial already showed real, measurable results published in a top medical journal. And its late-stage trial is 75%+ enrolled at Cleveland Clinic, Mayo Clinic, and Mass General.

The market is proven. The unmet need is massive. And late-stage data could be months away.

Read the full breakdown here

This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

Futures are edging higher after another record run, with traders leaning into hopes that the U.S. and Iran are getting closer to a deal. Oil is cooling, earnings are still doing their part, and a few big after-hours movers are keeping the risk-on mood alive.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• Shell PLC [SHEL]
• McDonald's Corporation [MCD]
• Canadian Natural Resources Limited [CNQ]
• Howmet Aerospace Inc. [HWM]

Earnings (Aftermarket):
• Gilead Sciences, Inc. [GILD]
• McKesson Corporation [MCK]
• MercadoLibre, Inc. [MELI]
• Cloudflare, Inc. [NET]
• Airbnb, Inc. [ABNB]
• Monster Beverage Corporation [MNST]

Economic Reports:
• Initial jobless claims (May 2): 8:30 am
• U.S. productivity (Q1): 8:30 am
• Construction spending (delayed report) (Feb.): 10:00 am
• Construction spending (March): 10:00 am
• Consumer credit (March): 3:00 pm

A major backer bought $34.7 million worth of shares across three straight sessions in a software stock down roughly 40% over the past year, while a 10% owner added another $2.2 million to a tiny biotech that has already surged more than 500%.

Insider readers get to see how this plays out under the hood and ways to actually take advantage of it.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money-back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

SiTime Corp (NASDAQ: SITM) delivered the kind of quarter that forces investors to rethink the whole business. First-quarter revenue hit $113.6 million, up 88% year over year, while non-GAAP EPS jumped to $1.44 from $0.26. Gross margin came in at 64.5%, operating margin reached 28%, and management raised 2026 revenue growth guidance to at least 80%.

The driver is clear. SiTime’s Communications, Enterprise & Data Center segment grew 158% year over year to $75.7 million, now making up about 67% of total revenue.

That segment is benefiting from AI inference, higher data center bandwidth needs, 1.6 Tb optical modules, and co-packaged optics designs. In other words, SiTime is no longer just a timing-chip company. It is becoming part of the physical layer that keeps AI infrastructure moving.

The stock is not cheap after a 275% one-year run and a 31% premarket surge, but this quarter backs up the move better than most AI-adjacent rallies. The company also ended the quarter with $789 million in cash, giving it room to keep investing.

My Take For You: This is a real AI infrastructure story with revenue, margins, and guidance all moving in the right direction. The stock is expensive, but the business just earned a much higher level of attention.

My Verdict: Buy this. The risk is that a massive post-earnings gap pulls forward too much upside at once.

Shell PLC (NYSE: SHEL) posted a strong quarter on the back of higher energy prices, but the market did not get everything it wanted. Adjusted earnings came in at $6.92 billion, ahead of the $6.1 billion consensus and well above the $5.58 billion reported a year earlier. The Iran war has pushed oil prices higher, and Shell’s operational performance helped turn that backdrop into a clear profit beat.

The complication is capital returns. Shell cut its quarterly buyback pace to $3 billion from $3.5 billion, even as it raised the dividend by 5%.

That is not a disaster, but it changes the tone. Investors were looking for the full Big Oil playbook: higher profits, higher cash returns, and clean balance sheet discipline. Instead, net debt rose to $52.6 billion from $45.7 billion at the end of last year.

The company also recently agreed to buy ARC Resources in a $16.4 billion deal, which could strengthen long-term output but adds another capital allocation question. Shell is still executing, but this is not the cleanest energy setup in the group.

My Take For You: Shell is benefiting from higher oil prices, but the reduced buyback and higher debt make this less compelling than the headline profit beat suggests.

My Verdict: Hold this. The risk is that falling oil prices expose the higher debt load and lower buyback pace.

A potential executive order tied to financial policy is drawing attention from market watchers.

Moves of this scale can ripple across currencies, savings, and hard assets.

With renewed focus on gold reserves and valuation, some believe a major shift could be unfolding.

Understanding the implications early may be key.

Learn how this could impact your strategy

Fortinet Inc (NASDAQ: FTNT) put up a clean quarter in a sector where investors still reward profitable growth. Non-GAAP EPS came in at $0.82, far above the $0.62 forecast, while revenue reached $1.85 billion, beating the $1.73 billion estimate. Total revenue rose 20% year over year, product revenue jumped 41%, and non-GAAP operating margin hit a first-quarter record of 35.8%.

That combination matters. A lot of cybersecurity companies can grow. Fewer can grow this fast while keeping margins this strong.

Fortinet is benefiting from demand across large enterprise, security operations, networking convergence, and its high-performance product portfolio. Management also guided for continued growth, with Q2 revenue projected around $1.82 billion and Q3 around $1.93 billion.

The stock’s 16% premarket move is big, but it is backed by a real beat across the income statement. Fortinet now looks less like a lagging cybersecurity name and more like a company the market had underpriced heading into the print.

My Take For You: Fortinet gave investors exactly what they needed: strong revenue growth, product momentum, and record margins. That is a rare combination in software and security right now.

My Verdict: Buy this. The risk is that competition or supply-chain pressure starts cutting into the margin strength that makes this quarter so attractive.

DoorDash is jumping because order demand is still stronger than skeptics expected. EPS came in at $0.42 versus $0.36 expected, gross order value hit $31.6 billion, and Q2 GOV guidance of $32.4 billion to $33.4 billion came in ahead of estimates. That matters more than the small revenue miss.

Fuel costs are the drag, with the Dasher gas relief program expected to cost more than $50 million, but the core demand story is holding up.

MKS is moving higher after TimesSquare Capital opened a new $66.2 million position, adding another institutional vote of confidence to a stock already up nearly 300% over the past year. The broader fund activity is mixed, but the market is clearly treating this fresh stake as a sign that big money still sees upside.

The valuation is not cheap at roughly 67x earnings, so this is not a bargain story. It is a momentum and institutional-flow story.

Snap is falling because the good parts of the quarter were not enough. Revenue rose 12% to $1.53 billion, daily active users reached 483 million, and adjusted EBITDA more than doubled to $233 million. But the cautious Q2 outlook and the end of the $400 million Perplexity AI deal are what traders care about today.

The bigger issue is still North America. User growth there remains weak, ad growth is sluggish, and Snap is relying more on cost cuts and subscriptions to support the story.

A small biotech just passed 75% enrollment in a late-stage clinical trial at some of the top heart centers in the U.S. - Cleveland Clinic, Mayo Clinic, Mass General, and Columbia.

The company's drug already showed clear, measurable results in a mid-stage trial published in a leading medical journal. Now it's going after a recurring heart condition where the only approved treatment is a weekly injection expected to do nearly $950 million in sales this year - and 82% of patients still aren't being treated.

Wall Street already has two Buy ratings on the stock with price targets 3-4x the current share price.

Get the full report

This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.